Inotek Pharmaceuticals Corporation
100 Cummings Center
Suite 419E
Beverly
Massachusetts
01915
United States
Tel: 978-232-9660
Fax: 978-232-8975
Website: http://www.inotekcorp.com/
Email: ngrant@inotekcorp.com
90 articles about Inotek Pharmaceuticals Corporation
-
Rocket Pharmaceuticals and Inotek Pharmaceuticals Complete Merger Transaction
1/4/2018
The combined company will be named Rocket Pharmaceuticals, Inc. and will focus on advancing a pipeline of gene therapy programs targeting rare and undertreated diseases.
-
This is definitely a list few, if any, companies want to be on.
-
Inotek Announces Filing Of Preliminary Proxy Statement For Proposed Merger With Clinical-Stage Gene Therapy Company, Rocket Pharmaceuticals
10/13/2017
-
Inotek Announces Merger Agreement With Rocket To Advance Pipeline Of First-In-Class Gene Therapies For Rare Diseases
9/13/2017
-
Vasuda Capital Management Send Demand Letter To Inotek Board
8/31/2017
-
Inotek Reports Second Quarter 2017 Financial Results And Operational Highlights
8/4/2017
-
Former Inotek Executive Jumps Ship to Flex as CEO
7/31/2017
-
Massachusetts' Inotek Exploring Strategic Alternatives After Another Glaucoma Trial Failure
7/10/2017
-
Inotek Announces Top-Line Results Of Phase II Fixed-Dose Combination Trial Of Trabodenoson And Provides Corporate Update
7/10/2017
-
Inotek Reports First Quarter 2017 Financial Results And Operational Highlights
5/10/2017
-
Inotek Presents Preclinical Data On Trabodenoson At Association for Research in Vision & Ophthalmology 2017 Annual Meeting
5/9/2017
-
Inotek Completes Patient Recruitment In Phase II Trial Of A Fixed-Dose Combination (FDC) Of Trabodenoson And Latanoprost
4/11/2017
-
Inotek Reports Fiscal Year 2016 Financial Results And Operational Highlights
3/16/2017
-
Inotek Plunges On Failed Phase III Glaucoma Trial
1/3/2017
-
Inotek Reports Third Quarter 2016 Financial Results And Operational Highlights
11/9/2016
-
Inotek To Present At The 2016 Ophthalmology Innovation Summit
10/7/2016
-
Inotek Appoints Timothy Barberich To Board Of Directors
9/29/2016
-
Inotek Announces Participation At Upcoming Investor Conferences
9/6/2016
-
Inotek Announces The Completion Of The Recruitment Phase Of MATrX-1, The First Phase 3 Clinical Trial Of Trabodenoson For Glaucoma
8/24/2016
-
Inotek Appoints Patrick Machado, JD, To Board Of Directors
8/18/2016